DK2992016T3 - Kombinationsterapi af et afucosyleret CD20-antistof med et CD79b-antistof-lægemiddelkonjugat - Google Patents
Kombinationsterapi af et afucosyleret CD20-antistof med et CD79b-antistof-lægemiddelkonjugat Download PDFInfo
- Publication number
- DK2992016T3 DK2992016T3 DK14724662.3T DK14724662T DK2992016T3 DK 2992016 T3 DK2992016 T3 DK 2992016T3 DK 14724662 T DK14724662 T DK 14724662T DK 2992016 T3 DK2992016 T3 DK 2992016T3
- Authority
- DK
- Denmark
- Prior art keywords
- antibody
- cd79b
- seq
- antibodies
- affinity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (6)
1. Obinutuzumab til anvendelse i kombination med CD79b-antistof-lægemiddelkonjugatet anti-CD79b-MC-vc-PAB-MMAE ved behandling af cancer, hvor anti-CD79b-antistoffet i CD79b-antistof-lægemiddelkonjugatet er huMA79b.v28, som omfatter det variable letkædedomæne SEQ ID NO: 69 og det variable tungkædedomæne SEQ ID NO: 70.
2. Obinutuzumab til anvendelse ifølge krav 1 i kombination med CD79b-antistof-lægemiddelkonjugatet anti-CD79b-MC-vc-PAB-MMAE ved behandling af cancer, kendetegnet ved, at der administreres et eller flere yderligere andre cytotoksika, kemoterapeutika eller anticancermidler eller forbindelser eller ioniserende stråling, som forstærker virkningerne af sådanne midler.
3. Obinutuzumab til anvendelse ifølge krav 1 eller 2 i kombination med CD79b-antistof-lægemiddelkonjugatet anti-CD79b-MC-vc-PAB-MMAE ved behandling af cancer, kendetegnet ved, at canceren er en CD20-udtrykkende cancer.
4. Obinutuzumab til anvendelse ifølge krav 3 i kombination med CD79b-antistof-lægemiddelkonjugatet anti-CD79b-MC-vc-PAB-MMAE ved behandling af cancer, kendetegnet ved, at den CD20-udtrykkende cancer er et lymfom eller lymfatisk leukæmi.
5. Sammensætning til anvendelse ved behandling af cancer, hvilken sammensætning omfatter obinutuzumab og CD79b-antistof-lægemiddelkonjugatet anti-CD79b-MC-vc-PAB-MMAE, hvor anti-CD79b-antistoffet i CD79b-antistof-lægemiddelkonjugatet er huMA79b.v28, som omfatter det variable letkædedomæne SEQ ID NO: 69 og det variable tungkædedomæne SEQ ID NO: 70.
6. Sammensætning til anvendelse ved behandling af cancer ifølge krav 5, kendetegnet ved, at der administreres et eller flere yderligere andre cytotoksika, kemoterapeutika eller anticancermidler eller forbindelser eller ioniserende stråling, som forstærker virkningerne af sådanne midler.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361818821P | 2013-05-02 | 2013-05-02 | |
| PCT/EP2014/058827 WO2014177615A2 (en) | 2013-05-02 | 2014-04-30 | COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH A CD79b ANTIBODY-DRUG CONJUGATE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2992016T3 true DK2992016T3 (da) | 2018-01-02 |
Family
ID=50733021
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14724662.3T DK2992016T3 (da) | 2013-05-02 | 2014-04-30 | Kombinationsterapi af et afucosyleret CD20-antistof med et CD79b-antistof-lægemiddelkonjugat |
Country Status (27)
| Country | Link |
|---|---|
| US (4) | US20140356352A1 (da) |
| EP (1) | EP2992016B1 (da) |
| JP (1) | JP6306154B2 (da) |
| KR (1) | KR101824311B1 (da) |
| CN (2) | CN121338026A (da) |
| AR (1) | AR096183A1 (da) |
| AU (1) | AU2014261454B2 (da) |
| BR (1) | BR112015027309A2 (da) |
| CA (1) | CA2908658C (da) |
| DK (1) | DK2992016T3 (da) |
| ES (1) | ES2653424T3 (da) |
| HK (1) | HK1213575A1 (da) |
| HR (1) | HRP20171897T1 (da) |
| HU (1) | HUE035171T2 (da) |
| IL (1) | IL242163B (da) |
| LT (1) | LT2992016T (da) |
| MX (1) | MX359964B (da) |
| MY (1) | MY181960A (da) |
| NO (1) | NO3080382T3 (da) |
| NZ (1) | NZ713745A (da) |
| PL (1) | PL2992016T3 (da) |
| PT (1) | PT2992016T (da) |
| RS (1) | RS56688B1 (da) |
| RU (1) | RU2670971C9 (da) |
| SG (1) | SG11201509009WA (da) |
| SI (1) | SI2992016T1 (da) |
| WO (1) | WO2014177615A2 (da) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2657253T3 (da) * | 2008-01-31 | 2017-10-09 | Genentech Inc | Anti-CD79b-antistoffer og immunkonjugater og fremgangsmåder til anvendelse |
| CA2979671C (en) * | 2014-09-23 | 2020-03-10 | Genentech, Inc. | Methods of using anti-cd79b immunoconjugates |
| IL313608A (en) * | 2015-12-09 | 2024-08-01 | Hoffmann La Roche | Antibody against CD20 type II to reduce the formation of antibodies against drugs |
| CN108700598A (zh) | 2016-03-25 | 2018-10-23 | 豪夫迈·罗氏有限公司 | 多路总抗体和抗体缀合的药物量化测定法 |
| US20180140703A1 (en) * | 2016-11-18 | 2018-05-24 | The Regents Of The University California | Tumor radiosensitization with antibody conjugates |
| CA3045944A1 (en) | 2016-12-07 | 2018-06-14 | Progenity, Inc. | Gastrointestinal tract detection methods, devices and systems |
| CA3054632A1 (en) | 2017-03-30 | 2018-10-04 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device |
| CR20250325A (es) * | 2018-04-13 | 2025-08-29 | Genentech Inc | Formulaciones inmunoconjugadas anti-cd79b estables (divisional expediente 2020-0550) |
| US20230041197A1 (en) | 2018-06-20 | 2023-02-09 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
| US12227565B2 (en) | 2018-06-20 | 2025-02-18 | Biora Therapeutics, Inc. | Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine |
| CN113348011B (zh) | 2018-11-19 | 2023-04-18 | 比奥拉治疗股份有限公司 | 用生物治疗剂治疗疾病的方法和装置 |
| CA3127556A1 (en) | 2019-01-28 | 2020-08-06 | Tuojie Biotech (Shanghai) Co., Ltd. | Anti-cd79b antibody, antigen-binding fragment thereof, and pharmaceutical use thereof |
| CN121197633A (zh) | 2019-12-13 | 2025-12-26 | 比特比德科有限责任公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
| CN112094345B (zh) * | 2020-06-01 | 2024-01-05 | 普众发现医药科技(上海)有限公司 | 可应用于肿瘤细胞捕获的小鼠抗免疫球蛋白关联βCD79b的单克隆抗体 |
| EP4190812A4 (en) * | 2020-07-27 | 2024-09-04 | Tuojie Biotech (Shanghai) Co., Ltd. | ANTI-CD79B ANTIBODY-DRUG CONJUGATE, ITS PREPARATION METHOD AND ITS PHARMACEUTICAL USE |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6922984B2 (en) * | 2003-08-27 | 2005-08-02 | Valero Refining Company - California | Heat recovery circuit |
| HUE038955T2 (hu) * | 2003-11-05 | 2018-12-28 | Roche Glycart Ag | Antigén-kötõ molekulák fokozott Fc receptor-kötõ affinitással és effektor funkcióval |
| ES2382627T3 (es) * | 2004-06-29 | 2012-06-12 | B.R.A.H.M.S Gmbh | Nuevos anticuerpos monoclonales estimuladores o bloqueadores de la tiroides, secuencias peptídicas que corresponden a sus regiones variables, y sus usos en medicina diagnóstica, preventiva y terapéutica |
| PT2474557E (pt) * | 2007-07-16 | 2014-12-03 | Genentech Inc | Anticorpos e imunoconjugados anti-cd79b e métodos de utilização |
| DK2657253T3 (da) * | 2008-01-31 | 2017-10-09 | Genentech Inc | Anti-CD79b-antistoffer og immunkonjugater og fremgangsmåder til anvendelse |
-
2014
- 2014-04-30 SI SI201430518T patent/SI2992016T1/en unknown
- 2014-04-30 PT PT147246623T patent/PT2992016T/pt unknown
- 2014-04-30 WO PCT/EP2014/058827 patent/WO2014177615A2/en not_active Ceased
- 2014-04-30 DK DK14724662.3T patent/DK2992016T3/da active
- 2014-04-30 HK HK16101476.3A patent/HK1213575A1/zh unknown
- 2014-04-30 KR KR1020157034237A patent/KR101824311B1/ko active Active
- 2014-04-30 BR BR112015027309A patent/BR112015027309A2/pt not_active Application Discontinuation
- 2014-04-30 AR ARP140101794A patent/AR096183A1/es unknown
- 2014-04-30 EP EP14724662.3A patent/EP2992016B1/en active Active
- 2014-04-30 RU RU2015151454A patent/RU2670971C9/ru active
- 2014-04-30 PL PL14724662T patent/PL2992016T3/pl unknown
- 2014-04-30 US US14/266,443 patent/US20140356352A1/en not_active Abandoned
- 2014-04-30 HU HUE14724662A patent/HUE035171T2/en unknown
- 2014-04-30 LT LTEP14724662.3T patent/LT2992016T/lt unknown
- 2014-04-30 HR HRP20171897TT patent/HRP20171897T1/hr unknown
- 2014-04-30 ES ES14724662.3T patent/ES2653424T3/es active Active
- 2014-04-30 MX MX2015015091A patent/MX359964B/es active IP Right Grant
- 2014-04-30 RS RS20171301A patent/RS56688B1/sr unknown
- 2014-04-30 CN CN202511437572.0A patent/CN121338026A/zh active Pending
- 2014-04-30 CN CN201480023250.5A patent/CN105189558A/zh active Pending
- 2014-04-30 AU AU2014261454A patent/AU2014261454B2/en active Active
- 2014-04-30 NZ NZ713745A patent/NZ713745A/en unknown
- 2014-04-30 MY MYPI2015703902A patent/MY181960A/en unknown
- 2014-04-30 JP JP2016511053A patent/JP6306154B2/ja active Active
- 2014-04-30 CA CA2908658A patent/CA2908658C/en active Active
- 2014-04-30 SG SG11201509009WA patent/SG11201509009WA/en unknown
- 2014-12-03 NO NO14820742A patent/NO3080382T3/no unknown
-
2015
- 2015-10-19 IL IL242163A patent/IL242163B/en active IP Right Grant
-
2017
- 2017-11-09 US US15/808,795 patent/US20180133315A1/en not_active Abandoned
-
2018
- 2018-08-10 US US16/101,203 patent/US20180344848A1/en not_active Abandoned
-
2020
- 2020-12-18 US US17/127,697 patent/US20210138065A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210138065A1 (en) | COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH A CD79b ANTIBODY-DRUG CONJUGATE | |
| JP7641323B2 (ja) | 治療抗体およびその使用 | |
| RU2739617C2 (ru) | Конъюгаты антитело-лекарственное средство (adc), которые связываются с белками flt3 | |
| EP2992015B1 (en) | Combination therapy of an afucosylated cd20 antibody with a cd22 antibody-drug conjugate |